Details for Patent: 12,186,322
✉ Email this page to a colleague
Which drugs does patent 12,186,322 protect, and when does it expire?
Patent 12,186,322 protects TADLIQ and is included in one NDA.
This patent has nine patent family members in nine countries.
Summary for Patent: 12,186,322
| Title: | Liquid oral formulations for tadalafil |
| Abstract: | The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc. |
| Inventor(s): | Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya |
| Assignee: | Liqmeds Worldwide Ltd |
| Application Number: | US18/665,714 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,186,322
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,186,322
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018397436 | ⤷ Start Trial | |||
| Brazil | 112020012986 | ⤷ Start Trial | |||
| Canada | 3086881 | ⤷ Start Trial | |||
| China | 111683683 | ⤷ Start Trial | |||
| European Patent Office | 3731870 | ⤷ Start Trial | |||
| Japan | 2021509114 | ⤷ Start Trial | |||
| Morocco | 50320 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
